Holiday weight regain on tirzepatide: what the data actually says

What's this video probably claiming?

Based on the caption, @pinkmathteacher is sharing a relatable post-holiday story: she took a break from cardio, ate freely over Christmas, gained some weight, and is now back to her routine of 10,000 daily steps and intermittent fasting while continuing compounded tirzepatide at 7.5mg. The implicit claim is that this combination, GLP-1 medication plus moderate movement plus time-restricted eating, is a manageable and effective framework for weight loss, and that short-term holiday weight gain is reversible within this system. She's framing the regain as a bump, not a failure. That's a reasonable framing, but it carries several assumptions worth interrogating: that 7.5mg is a meaningful dose, that intermittent fasting adds real benefit on top of tirzepatide, and that step counts are a valid proxy for metabolic health. Each of those claims has a more complicated answer than a TikTok caption can hold.

What does the science actually show?

Tirzepatide's weight loss data is genuinely impressive. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on 15mg tirzepatide lost a mean of 20.9% of body weight over 72 weeks. Lower doses, including the 10mg arm, produced around 19.5% loss. The 5mg arm came in at roughly 15%. So 7.5mg, which sits between those studied doses, would theoretically land somewhere in that range, though that specific dose wasn't the primary endpoint in SURMOUNT-1. On intermittent fasting combined with GLP-1 therapy, the evidence is thinner. A 2023 study in Obesity (Liu et al.) found time-restricted eating added modest additional weight loss when layered onto lifestyle intervention, but there's no strong RCT specifically combining tirzepatide with intermittent fasting to confirm synergistic effects. Step count data is similarly imprecise as a clinical metric, though 10,000 steps correlates with meaningful cardiovascular outcomes in observational data (Paluch et al., 2022, JAMA Internal Medicine).

Where does the social media noise diverge from clinical reality?

The GLP-1 TikTok community has developed a folk wisdom around these medications that sometimes runs ahead of the evidence. A few patterns worth flagging here. First, compounded tirzepatide is not equivalent to Zepbound or Mounjaro. The FDA has been explicit about this. Compounded versions may vary in concentration, excipients, and sterility standards, and the agency removed tirzepatide from its drug shortage list in 2024, which triggered restrictions on compounding. Creators rarely address this distinction, and that silence misleads viewers who assume compounded equals brand-name at lower cost. Second, the framing of holiday weight gain as purely behavioral, fixed by returning to steps and fasting, understates the hormonal complexity involved. GLP-1 receptor agonists reduce appetite signaling, but caloric surpluses during medication pauses or dose holds can still produce fat regain that takes longer to reverse than the social media timeline suggests. Third, combining intermittent fasting with appetite-suppressing medications raises real questions about adequate protein and micronutrient intake that almost no creator addresses.

What should you actually know?

Short-term weight fluctuations during holidays are mostly water, glycogen, and gut content, not actual fat mass. Studies on glycogen storage suggest a single high-carbohydrate event can add 1 to 2 kilograms of water weight within 24 hours (Acheson et al., 1988, American Journal of Clinical Nutrition). So some of what this creator gained over Christmas is likely not the fat regain it might visually appear to be. That's worth knowing if you're on a similar medication and panicking after New Year's. However, the longer a person is off structured eating and movement, the more genuine fat regain becomes a risk, particularly because tirzepatide's appetite suppression doesn't fully compensate for highly palatable, calorie-dense holiday foods. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that stopping tirzepatide after 36 weeks led to regaining about two-thirds of lost weight within a year, confirming these medications work while you're on them, not permanently. Lifestyle habits matter even on effective pharmacotherapy.